DEFA14A: Milestone Pharmaceuticals Refreshes Board with New Director Appointments and Cooperation Agreement with Alta Fundamental Advisers

Milestone Pharmaceuticals has appointed two new independent directors, Stuart M. Duty and Andrew R. Saik, to its Board of Directors and entered into a cooperation agreement with Alta Fundamental Advisers LLC.

Summary

• Milestone Pharmaceuticals has entered into a Cooperation Agreement with Alta Fundamental Advisers LLC, resulting in changes to the company's Board of Directors.
• The Board size has been increased to nine directors with the immediate appointment of Stuart M. Duty and Andrew R. Saik as new independent directors.
• A third independent director, mutually agreed upon by the Company and Alta, will be appointed to the Board before September 6, 2024.
• Alta Fundamental Advisers Master L.P. has withdrawn its intention to nominate five directors at the 2024 Annual Meeting.
• The company will nominate the initial new directors for election at both the 2024 and 2025 annual meetings.
• Debra K. Liebert and Richard Pasternak will not stand for reelection at the 2024 Annual Meeting, and the Board size will decrease to eight directors after the meeting and the appointment of the Company Identified New Director.
• The 2024 Annual Meeting is scheduled for August 28, 2024.
• Alta has agreed to vote its shares in accordance with the Board's recommendations, with certain exceptions.

Sentiment

Score: 7

Explanation: The document reflects a positive resolution to potential shareholder activism, with the company reaching an agreement with Alta and adding experienced directors to the board. The tone is generally optimistic.

Positives

• The addition of Stuart M. Duty and Andrew R. Saik brings significant experience in investment banking, operations, accounting, and finance to the Board.
• The Cooperation Agreement with Alta Fundamental Advisers avoids a potential proxy contest and provides stability to the Board.
• The agreement includes customary standstill, non-disparagement, and expense reimbursement provisions, which are generally favorable for the company.
• Alta's commitment to vote its shares in accordance with the Board's recommendations provides support for the company's strategic direction.

Negatives

• The agreement with Alta includes a voting commitment from Alta, which could limit its ability to act independently on certain matters.
• The agreement includes a standstill provision that restricts Alta's ability to acquire additional shares or engage in certain activities related to the company.

Risks

• The Cooperation Agreement could be terminated if either party materially breaches its obligations, potentially leading to renewed uncertainty.
• The company's reliance on Alta's voting commitment could be a risk if Alta's interests diverge from those of other shareholders.
• The standstill provision could limit Alta's ability to advocate for changes that could benefit shareholders.

Future Outlook

The company plans to continue its focus on developing and commercializing innovative cardiovascular medicines. The newly appointed directors are expected to provide valuable insights as the company approaches an exciting time.

Management Comments

• Robert J. Wills, PhD, Chairman of the Milestone Board of Directors, stated, 'We welcome Stuart and Andrew to our Board and look forward to benefitting from their varied perspectives and experiences.'
• Dr. Wills added, 'We believe Stuart and Andrew will provide important insights to the Board and are great additions as we approach this particularly exciting time for Milestone.'
• Dr. Wills also stated, 'We want to thank Debra and Richard for their years of service and significant contributions as members of the Board.'

Industry Context

This announcement reflects a trend of increased shareholder activism and engagement in corporate governance matters. Companies are increasingly working with activist investors to reach agreements that avoid proxy contests and bring fresh perspectives to the board.

Comparison to Industry Standards

• Cooperation agreements are a common tool used by companies to manage relationships with activist investors, similar to agreements seen with companies like Amarin Corporation and Sarissa Capital.
• The board refreshment process is in line with industry best practices for ensuring board diversity and expertise, comparable to changes implemented at companies like Biogen and Third Point.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The agreement with Alta and the board refreshment are intended to enhance shareholder value.
• Employees: The changes in board composition could impact the company's strategic direction and operations.
• Customers: The company's focus on developing and commercializing innovative cardiovascular medicines is expected to benefit patients with heart conditions.

Next Steps

• The Company will appoint a third independent director to its Board in the near term.
• The Company will hold its 2024 Annual Meeting on August 28, 2024.
• The Company will file its definitive proxy statement for the Annual Meeting with the SEC and Canadian securities regulatory authorities.

Key Dates

Keywords

Board of Directors, Cooperation Agreement, Milestone Pharmaceuticals, Alta Fundamental Advisers, Director Appointments, Shareholder Agreement, Corporate Governance